Insights

Executive Summary Generic pharmaceutical companies face a structural cost squeeze that has worsened since 2016. Teva, Mylan, and Sun Pharma […]

A deep-dive pillar page for pharma/biotech IP teams, R&D leads, and institutional investors. Part 1: The R&D Productivity Crisis —

Why Formulary Management Is Now an IP Discipline The pharmaceutical formulary started its modern life as an administrative cost control

The 80/80 Paradox: What the Numbers Actually Say The U.S. pharmaceutical market runs on a structural contradiction that no other

The United States pharmaceutical market operates within a network of opaque intermediaries that disconnect manufacturing costs from patient expenditures. Billionaire

1. Why Patent Defense Is a Corporate Strategy Problem, Not a Legal One Patent defense gets handed to legal teams.

1. Executive Summary The pharmaceutical industry’s API manufacturing layer is undergoing a structural break, not an upgrade cycle. The convergence

A deep-dive for pharma IP teams, portfolio managers, and institutional investors on the strategies, IP valuations, and commercial mechanics that

The biopharma industry has spent decades optimizing for efficiency. Lean supply chains, single-source API relationships, centralized cell storage, and just-in-time